REG - Abingdon Health PLC - Result of AGM

Abingdon HealthAnnouncement

19/11/2024 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241119:nRSS8264Ma&default-theme=true

RNS Number : 8264M  Abingdon Health PLC  19 November 2024

 

 

19 November 2024

 

Abingdon Health Plc

("Abingdon" or the "Company")

 

Result of Annual General Meeting

 

Abingdon Health plc (AIM:ABDX), a leading international lateral flow contract
development and manufacturing organisation, is pleased to announce that at the
Annual General Meeting held earlier today, all resolutions were duly passed
with greater than 99.8% of votes in favour.

 

Enquiries

 

 Abingdon Health plc                                                             www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                            Via Walbrook PR
 Chris Hand, Executive Chairman

 Zeus (Sole Broker and Nominated Adviser)                                          Tel: +44 (0) 20 3829 5000
 Chris Fielding / Alexandra Campbell-Harris (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
 Phillip Marriage                              +44 (0)7867 984 082

 

The person responsible for arranging the release of this announcement on
behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

About Abingdon Health plc

Abingdon Health is a leading med-tech contract service provider offering its
services to an international customer base.

 

The Group's CDMO division (https://www.abingdonhealth.com/services/)  offers
lateral flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format. Abingdon Health's
CDMO division has the internal capabilities to take lateral flow projects, in
areas such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing, from initial concept
through to routine and large-scale manufacturing; from "idea to commercial
success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life
Sciences) (https://cslifesciences.com/)  and IVDeology
(https://www.ivdeology.co.uk/) , provide a broad range of regulatory services
to the in vitro diagnostic and wider medical device industry, to support
customers in bringing products to market across a range of territories
including the USA, EU and the UK. Our consultancy services range from design,
implementation and maintenance of quality management systems, preparation of
technical files for regulatory approvals, part-time and interim management
support, auditing both internal and external, management reviews and
presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com/)  e-commerce site offers consumers a
range of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGQKCBPDBDDKDD